Skoči na glavni sadržaj

Libri Oncologici : Croatian Journal of Oncology, Vol. 45 No. 2-3, 2017.

Pregledni rad

Prostate cancer immunotherapy

Antonio Juretić orcid id orcid.org/0000-0002-6379-9708 ; Department of Clinical Oncology, School of Medicine, University of Zagreb, Zagreb, Croatia; Oncology Clinic, University Hospital Center Zagreb, Zagreb, Croatia

Puni tekst: engleski pdf 142 Kb

str. 69-71

preuzimanja: 403

citiraj

Sažetak

Prostate cancer is one of the most commonly diagnosed cancers in men and also one of the leading causes of their cancer-related deaths. Despite recent advances in the treatment of metastatic castration resistant prostate cancer, agents providing durable disease control and long-term survival are still needed. Therefore, various anti-cancer immunotherapy approaches are being explored in prostate cancer patients. This review provides a short overview of the various approaches. However, apart from the vaccine sipuleucel-T which has received approval from the US Food and Drug Administration (FDA), the majority of other approaches have still not reached phase 3 clinical trials.

Ključne riječi

prostate cancer; immunotherapy; vaccines

Hrčak ID:

192193

URI

https://hrcak.srce.hr/192193

Datum izdavanja:

21.12.2017.

Podaci na drugim jezicima: hrvatski

Posjeta: 2.048 *